Lopinavir and ritonavir

Phase 3Small molecule

SSociedad Andaluza de Enfermedades Infecciosas

Lopinavir and ritonavir is one of 20 small molecule programs targeting COVID-19. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Lopinavir and ritonavir

SSociedad Andaluza de Enfermedades Infecciosas

Phase 3

1 2

Nexavar

Bayer

Preclinical

1 3

Singulair

AstraZeneca

Preclinical

1 4

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 5

Nitrostat

VViatris Specialty LLC

Preclinical

1 6

Rayaldee

OOrganon and Co

Preclinical

1 7

SARS-COV-2 VACCINE

Moderna

Preclinical

2 8

Achromycin V

WWyeth-Lederle Vaccines

Statins

1 10

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1/2Recruiting

Advanced/metastatic Solid Tumors

NCT05914116

Clinical

Trials by Indication[1]

Quality of Life1 trial

Clinical Trial, Open-label, Randomised, in Order to Compare the Quality of Life for Those VIH+ Patients That Start With Monotherapy on LPV/r Tablets Vs. Triple Therapy With a Boosted Protease Inhibitor

Completed·SSociedad Andaluza de Enfermedades Infecciosas·Phase 4·NCT01166477·228 enrolled

COVID-191 trial

Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers

Terminated·—·Phase 3·NCT04328285·118 enrolled

Corona Virus Infection1 trial

The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection

Completed·GGuangzhou 8th People's Hospital·Phase 4·NCT04252885·86 enrolled

Advanced/Metastatic Solid Tumors1 trial

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Recruiting·DDualityBio Inc.·Phase 1/2·NCT05914116·862 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Lopinavir and ritonavir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lopinavir and ritonavir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lopinavir and ritonavir. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sociedad Andaluza de Enfermedades Infecciosas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSociedad Andaluza de Enfermedades Infecciosas

Lopinavir and ritonavir

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Quality of Life1 trial

COVID-191 trial

Corona Virus Infection1 trial

Advanced/Metastatic Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News